The Oncology Institute, Inc. (NASDAQ:TOI) Director Mark L. Pacala Buys 90,562 Shares

The Oncology Institute, Inc. (NASDAQ:TOI) Director Mark L. Pacala purchased 90,562 shares of Oncology Institute stock in a transaction that occurred on Wednesday, March 26th. The shares were bought at an average cost of $1.04 per share, with a total value of $94,184.48. Following the completion of the transaction, the director now directly owns 224,971 shares of the company’s stock, valued at approximately $233,969.84. The trade was a 67.38 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Oncology Institute Stock Up 2.7 %

TOI opened at $1.14 on Friday. The stock has a market cap of $86.14 million, a PE ratio of -1.46 and a beta of 0.41. The company has a current ratio of 2.49, a quick ratio of 2.27 and a debt-to-equity ratio of 5.91. The stock’s fifty day simple moving average is $0.86 and its 200 day simple moving average is $0.48. The Oncology Institute, Inc. has a 1-year low of $0.13 and a 1-year high of $1.63.

Oncology Institute (NASDAQ:TOI) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.06). Oncology Institute had a negative net margin of 17.63% and a negative return on equity of 186.83%. The company had revenue of $100.27 million during the quarter, compared to analyst estimates of $109.15 million.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. HighTower Advisors LLC boosted its stake in shares of Oncology Institute by 190.8% in the 3rd quarter. HighTower Advisors LLC now owns 81,362 shares of the company’s stock valued at $27,000 after purchasing an additional 53,382 shares during the last quarter. Jane Street Group LLC increased its stake in Oncology Institute by 613.6% in the fourth quarter. Jane Street Group LLC now owns 127,659 shares of the company’s stock valued at $39,000 after purchasing an additional 109,769 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Oncology Institute during the 4th quarter worth about $41,000. Renaissance Technologies LLC increased its position in Oncology Institute by 7.1% in the 4th quarter. Renaissance Technologies LLC now owns 182,000 shares of the company’s stock valued at $56,000 after buying an additional 12,000 shares in the last quarter. Finally, FreeGulliver LLC grew its stake in Oncology Institute by 219.3% in the fourth quarter. FreeGulliver LLC now owns 600,747 shares of the company’s stock valued at $186,000 after acquiring an additional 412,578 shares during the period. Institutional investors own 36.86% of the company’s stock.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.